ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURE MARKET FORECAST 2019-2027
Asia Pacific Viral Vector Vaccines Manufacturing Market by Types 2019-2027 (Adenoviral Vectors, Retroviral Vectors, Lent Viral Vectors, Adeno-associated Viral Vectors, Poxvirus, Cytomegalovirus, Other Viral Vectors) by Application (Multivalent, Multipathogen) by Diseases (Human Diseases, Veterinary Diseases) by Geography.
The Asia Pacific regional market for the manufacture of viral vector vaccines is expected to have CAGR of 18.01% during the forecast period of 2019-2027. Advanced viral vector vaccines for the treatment of chronic and infectious diseases are also expected to boost the growth of the market in the Asia-Pacific region.
The strategies adopted by the key market players in Japan and the government initiatives promoting clinical trials in India are the key factors driving growth in the Asia-Pacific viral vector vaccine manufacturing market. The viral vector vaccine manufacturing market is also driven by the government approvals to conduct trials related to the Ebola virus disease vaccine. An increasing number of clinical trials related to viral vector vaccine in China also drives the growth of the viral vector vaccine manufacturing market in this country. Additionally, the high prevalence of avian flu in China is contributing to the increased demand of the viral vector vaccine manufacturing market.
Leading market players in the Asia Pacific viral vector vaccine manufacturing market are Advanced Biotherapeutics Consulting, Advanced Bioscience Laboratories Inc., Biogen Idec (Now Biogen Inc.), Benitec Biopharma, Boehringer Ingelheim Gmbh, Cell And Gene Therapy Catapult, Biovian, Id Pharma Co. Ltd., Ceva Corporate, Cobra Biologics (Subsidiary Of Recip Ab), Applied Viromics, Batavia Biosciences, Brammer Bio, Ge Healthcare and Janssen Pharmaceutical Inc.
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- POX VIRUS CONSTITUTES THE LARGEST MARKET SHARE IN TERMS OF TYPES
- HUMAN DISEASES ARE ANTICIPATED TO GROW SIGNIFICANTLY DURING THE FORECAST PERIOD
- MULTIVALENT APPLICATIONS ARE WIDELY USED IN THE VIRAL VECTOR MANUFACTURING MARKET
- MARKET DETERMINANTS
- MARKET DRIVERS
- PROMISING RESULTS FROM SEVERAL CLINICAL STUDIES
- MOUNTING NUMBER OF VIRAL VECTORS GENE-THERAPY-BASED CLINICAL TRIALS
- GROWING CHRONIC DISEASES
- MARKET OPPORTUNITIES
- SWELLING INVESTMENT IN GENE-THERAPY-BASED R&D ACTIVITIES
- INCREASE IN THE RESEARCH AND DEVELOPMENT
- MARKET RESTRAINTS
- POOR REIMBURSEMENT SYSTEM
- STRINGENT GOVERNMENT POLICIES
- MARKET CHALLENGES
- UNFAVOURABLE COMPENSATION SITUATION
- PRICING PRESSURE COUPLED WITH LACK OF PRODUCT DIFFERENTIATION
- RIGOROUS REGULATORY AGENDA
- MARKET DRIVERS
- MARKET SEGMENTATION
- MARKET BY TYPES 2019-2027
- ADENOVIRAL VECTORS
- RETROVIRAL VECTORS
- LENTIVIRAL VECTORS
- ADENO-ASSOCIATED VIRAL VECTORS
- POXVIRUS
- CYTOMEGALOVIRUS
- OTHER VIRAL VECTORS
- MARKET BY APPLICATION 2019-2027
- MULTIVALENT
- MULTIPATHOGEN
- MARKET BY DISEASES 2019-2027
- HUMAN DISEASES
- HEPATITIS
- CANCER
- MALARIA
- TUBERCULOSIS
- INFLUENZA
- HIV
- OTHER HUMAN DISEASES
- VETERINARY DISEASES
- AVIAN INFLUENZA
- MAREK’S DISEASE
- INFECTIOUS BRONCHITIS
- PPR DISEASE
- OTHER VETERINARY DISEASES
- HUMAN DISEASES
- MARKET BY TYPES 2019-2027
- KEY ANALYTICS
- EVOLUTION AND TRANSITION
- REGULATORY FRAMEWORK
- ASIA PACIFIC
- AUSTRALIA
- JAPAN
- INDIA
- CHINA
- KEY PROPERTIES OF VIRAL VECTOR
- CHARACTERISTICS OF POTENTIAL VIRAL VACCINE VECTORS
- PATENT ANALYSIS
- JAPAN PATENT ANALYSIS
- MANUFACTURING PROCESS OF A VIRAL-VECTOR
- SMALL-SCALE MANUFACTURING PROCESS OF ADENOVIRUS
- KEY SUPPLIERS IN VIRAL VECTOR MARKET
- KEY BUYING CRITERIA
- ASIA PACIFIC
- GEOGRAPHICAL ANALYSIS
- ASIA-PACIFIC
- CHINA
- INDIA
- JAPAN
- AUSTRALIA
- SOUTH KOREA
- REST OF ASIA-PACIFIC
- ASIA-PACIFIC
- COMPANY PROFILES
- ADVANCED BIOTHERAPEUTICS CONSULTING
- ADVANCED BIOSCIENCE LABORATORIES INC.
- APPLIED VIROMICS
- BATAVIA BIOSCIENCES
- BENITEC BIOPHARMA
- BIOGEN IDEC (NOW BIOGEN INC.)
- BIOVIAN
- BRAMMER BIO
- BOEHRINGER INGELHEIM GMBH
- CELL AND GENE THERAPY CATAPULT
- CEVA CORPORATE
- COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)
- GE HEALTHCARE
- JANSSEN PHARMACEUTICAL INC.
- ID PHARMA CO. LTD
LIST OF TABLES
TABLE 1 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)
TABLE 2 ONGOING CLINICAL TRIALS RELATED TO VIRAL VECTORS
TABLE 3 VARIOUS VIRAL VECTORS PROPERTIES AND THEIR APPLICATION IN GENE THERAPY
TABLE 4 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET BY TYPES 2019-2027 ($ THOUSANDS)
TABLE 5 KEY VIRAL VECTORS CHARACTERISTICS
TABLE 6 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENOVIRAL VECTORS 2019-2027 ($ THOUSANDS)
TABLE 7 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN RETROVIRAL VECTORS 2019-2027 ($ THOUSANDS)
TABLE 8 ADVANTAGES AND DISADVANTAGES OF RETROVIRAL VECTORS
TABLE 9 COMPONENTS OF HIV PROVIRUS
TABLE 10 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN LENTIVIRAL VECTORS 2019-2027 ($ THOUSANDS)
TABLE 11 SECOND- VS. THIRD-GENERATION LENTIVIRAL SYSTEMS
TABLE 12 AAV VECTORS WITH THEIR TROPISMS AND RECEPTORS
TABLE 13 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN ADENO-ASSOCIATED VIRAL VECTORS 2019-2027 ($ THOUSANDS)
TABLE 14 LICENSED FOWL POX VIRAL-VECTORED VETERINARY VACCINES
TABLE 15 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN POX VIRUS 2019-2027 ($ THOUSANDS)
TABLE 16 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN CYTOMEGALOVIRUS 2019-2027 ($ THOUSANDS)
TABLE 17 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN OTHER VIRAL VECTORS 2019-2027 ($ THOUSANDS)
TABLE 18 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET BY APPLICATION 2019-2027 ($ THOUSANDS)
TABLE 19 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIVALENT 2019-2027 ($ THOUSANDS)
TABLE 20 TB STATISTICS FOR 2016
TABLE 21 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN MULTIPATHOGEN 2019-2027 ($ THOUSANDS)
TABLE 22 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET BY DISEASES 2019-2027 ($ THOUSANDS)
TABLE 23 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES 2019-2027 ($ THOUSANDS)
TABLE 24 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN HUMAN DISEASES BY TYPES 2019-2027 ($ THOUSANDS)
TABLE 25 ASIA PACIFIC HUMAN DISEASES MARKET IN HEPATITIS 2019-2027 ($ THOUSANDS)
TABLE 26 ESTIMATED ACTUAL NEW CASES OF HAV
TABLE 27 ASIA PACIFIC HUMAN DISEASES MARKET IN CANCER 2019-2027 ($ THOUSANDS)
TABLE 28 ASIA PACIFIC HUMAN DISEASES MARKET IN MALARIA 2019-2027 ($ THOUSANDS)
TABLE 29 MALARIA VACCINE DEVELOPMENT INITIATIVES
TABLE 30 VIRAL VECTOR VACCINE CANDIDATES FOR TUBERCULOSIS
TABLE 31 ASIA PACIFIC HUMAN DISEASES MARKET IN TUBERCULOSIS 2019-2027 ($ THOUSANDS)
TABLE 32 ASIA PACIFIC HUMAN DISEASES MARKET IN INFLUENZA 2019-2027 ($ THOUSANDS)
TABLE 33 BENEFITS AND CONCERN FOR VIRUS-VECTORED EXPERIMENTAL INFLUENZA VACCINES
TABLE 34 ASIA PACIFIC HUMAN DISEASES MARKET IN HIV 2019-2027 ($ THOUSANDS)
TABLE 35 ASIA PACIFIC HUMAN DISEASES MARKET IN OTHER HUMAN DISEASES 2019-2027 ($ THOUSANDS)
TABLE 36 ONGOING CLINICAL TRIALS AND DEVELOPMENT IN ZIKA VIRUS VACCINE
TABLE 37 LICENSED VIRAL-VECTORED VETERINARY VACCINES
TABLE 38 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES 2019-2027 ($ THOUSANDS)
TABLE 39 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET IN VETERINARY DISEASES BY TYPES 2019-2027 ($ THOUSANDS)
TABLE 40 AVIAN INFLUENZA VACCINES
TABLE 41 ASIA PACIFIC VETERINARY DISEASES MARKET IN AVIAN INFLUENZA 2019-2027 ($ THOUSANDS)
TABLE 42 ASIA PACIFIC VETERINARY DISEASES MARKET IN MAREK’S DISEASE 2019-2027 ($ THOUSANDS)
TABLE 43 MAREK’S DISEASE VACCINES
TABLE 44 ASIA PACIFIC VETERINARY DISEASES MARKET IN INFECTIOUS BRONCHITIS 2019-2027 ($ THOUSANDS)
TABLE 45 ASIA PACIFIC VETERINARY DISEASES MARKET IN PPR DISEASE 2019-2027 ($ THOUSANDS)
TABLE 46 ASIA PACIFIC VETERINARY DISEASES MARKET IN OTHER VETERINARY DISEASES 2019-2027 ($ THOUSANDS)
TABLE 47 ASIA-PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)
TABLE 48 CHINA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)
TABLE 49 ONGOING PRECLINICAL AND CLINICAL TRIALS OF HIV/AIDS VACCINE IN CHINA
TABLE 50 PREVALENCE OF TUBERCULOSIS IN INDIA 2016
TABLE 51 INDIAVIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)
TABLE 52 CLINICAL TRIALS RELATED TO HIV VACCINE IN INDIA
TABLE 53 JAPAN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)
TABLE 54 AUSTRALIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)
TABLE 55 SOUTH KOREA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 BY TYPES ($ THOUSANDS)
TABLE 56 PRINCIPAL CAUSES OF DEATHS IN SINGAPORE, 2014–2016
TABLE 57 NUMBER OF HIV AND AIDS PEOPLE IN THAILAND 2016
LIST OF FIGURES
FIGURE 1 ASIA PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSAND)
FIGURE 2 SCHEMATIC OVERVIEW OF MULTIVALENT AND MULTIPATHOGEN VIRAL VECTOR VACCINES
FIGURE 3 ESTIMATION OF PEOPLE LIVING WITH HIV 2016 (MILLION)
FIGURE 4 PREVALENCE OF HBV INFECTION IN THE GENERAL POPULATION 2015 (MILLIONS)
FIGURE 5 VACCINE ADVANCEMENTS TIMELINE
FIGURE 6 STEPS REQUIREMENT FOR VACCINE APPROVAL
FIGURE 7 VACCINE REVIEW AND REGULATION STEPS UNDER MHLW
FIGURE 8 APPROVAL PROCESS OF VACCINE IN INDIA
FIGURE 9 MANUFACTURING PROCESS OF ADENOVIRUS
FIGURE 10 CHINA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)
FIGURE 11 INDIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)
FIGURE 12 JAPAN VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)
FIGURE 13 NUMBER OF HIV CASES IN JAPAN 2012 AND 2016
FIGURE 14 AUSTRALIA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)
FIGURE 15 VARIOUS VIRAL VACCINE VECTORS USED IN AIDS VACCINE DEVELOPMENT
FIGURE 16 NUMBER OF DIAGNOSED HIV INFECTIONS IN AUSTRALIA 2012–2016
FIGURE 17 SOUTH KOREA VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)
FIGURE 18 SHARES OF DEATH IN SOUTH KOREA IN 2016 DEATH RATE (PER 100,000 POPULATIONS)
FIGURE 19 REST OF ASIA-PACIFIC VIRAL VECTOR VACCINE MANUFACTURING MARKET 2019-2027 ($ THOUSANDS)
- GEOGRAPHICAL ANALYSIS
- ASIA-PACIFIC
- CHINA
- INDIA
- JAPAN
- AUSTRALIA
- SOUTH KOREA
- REST OF ASIA-PACIFIC
- ASIA-PACIFIC
- MARKET SEGMENTATION
- MARKET BY TYPES 2019-2027
- ADENOVIRAL VECTORS
- RETROVIRAL VECTORS
- LENTIVIRAL VECTORS
- ADENO-ASSOCIATED VIRAL VECTORS
- POXVIRUS
- CYTOMEGALOVIRUS
- OTHER VIRAL VECTORS
- MARKET BY APPLICATION 2019-2027
- MULTIVALENT
- MULTIPATHOGEN
- MARKET BY DISEASES 2019-2027
- HUMAN DISEASES
- HEPATITIS
- CANCER
- MALARIA
- TUBERCULOSIS
- INFLUENZA
- HIV
- OTHER HUMAN DISEASES
- VETERINARY DISEASES
- AVIAN INFLUENZA
- MAREK’S DISEASE
- INFECTIOUS BRONCHITIS
- PPR DISEASE
- HUMAN DISEASES
- MARKET BY TYPES 2019-2027
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.